lapatinib has been researched along with Cancer of Salivary Gland in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, Y; Aoyama, J; Hatano, T; Hirai, Y; Kijima, N; Nishimura, G; Nojima, Y; Oridate, N; Sano, D; Takada, K; Takahashi, H | 1 |
| Bastida, CC; Falchook, GS; Kurzrock, R; Lippman, SM | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Agulnik, M; Chen, EX; Cohen, EE; Cohen, RB; Dancey, J; Hayes, DN; Ho, J; Hotte, S; Laurie, S; Pond, GR; Siu, LL; Tsao, MS; Vidal, L; Winquist, E | 1 |
| Azuma, T; Fujishiro, Y; Matsuzaka, K; Ochiai, H; Tonogi, M; Yamane, GY | 1 |
| Laurie, SA; Licitra, L | 1 |
| Agulnik, M; Brown, S; Chen, EX; Cohen, EW; Cohen, RB; Dancey, JE; Daneshmand, M; Hayes, DN; Ho, J; Hotte, SJ; Laurie, S; Lorimer, I; Pond, GR; Siu, LL; Tsao, MS; Vokes, EE; Winquist, E | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
2 review(s) available for lapatinib and Cancer of Salivary Gland
| Article | Year |
|---|---|
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
3 trial(s) available for lapatinib and Cancer of Salivary Gland
| Article | Year |
|---|---|
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Infusions, Intravenous; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Receptor, ErbB-2; Reference Values; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Disease-Free Survival; Epidermal Growth Factor; Female; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Salivary Gland Neoplasms; Treatment Outcome | 2007 |
3 other study(ies) available for lapatinib and Cancer of Salivary Gland
| Article | Year |
|---|---|
Effect of HER2-targeted therapy on PDX and PDX-derived organoids generated from HER2-positive salivary duct carcinoma.
Topics: Animals; Carcinoma, Ductal; Humans; Lapatinib; Mice; Receptor, ErbB-2; Salivary Ducts; Salivary Gland Neoplasms; Signal Transduction | 2023 |
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm, Residual; Quinazolines; Receptor, ErbB-2; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab; Vascular Endothelial Growth Factor A | 2014 |
The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salivary Gland Neoplasms; Side-Population Cells | 2012 |